Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
Scientific presentation

Do More Single Cell with Less – Tapestri Platform Expansion for Hematologic Malignancy Research


Koichi Takahashi, MD, PhD, MD Anderson Cancer Center & Jim Flynn, PhD, Mission Bio
Description

Watch this webinar to hear the highlights of the Tapestri Platform expansion and learn how you can do more single cell in less time with lower sample input to enable new avenues for your research that were previously impossible.

We’re also joined by Dr. Koichi Takahashi of MD Anderson Cancer Center who discusses his work in AML research using novel multi-omics applications.

Speaker Abstract:
Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment resistance. Here, using single-cell DNA sequencing, we report the clonal architecture and mutational histories of 123 acute myeloid leukemia (AML) patients. The single-cell data reveals cell-level mutation co-occurrence and enables reconstruction of mutational histories characterized by linear and branching patterns of clonal evolution, with the latter including convergent evolution. Through xenotransplantation, we show leukemia-initiating capabilities of individual subclones evolving in parallel. Also, by simultaneous single-cell DNA and cell surface protein analysis, we illustrate both genetic and phenotypic evolution in AML. Lastly, single-cell analysis of longitudinal samples reveals the underlying evolutionary process of therapeutic resistance. Together, these data unravel clonal diversity and evolution patterns of AML and highlight their clinical relevance in the era of precision medicine.



VIEW


Scientific presentation
AML Single-cell Multi-omics MRD (scMRD) and the Horizon of Clinical Utility
Aaron Llanso
AMP 2022 (2022)
Scientific presentation
Molecular Analysis of Acute Myeloid Leukemia in Morphologic Remission
Sanam Loghavi, MD
AMP 2022 (2022)
Scientific presentation
Considerations, Strategies, and Advances in Early Drug Development to Mitigate Clinical Holds and Achieve Successful CGT Outcomes
Azadeh Golipour, PhD, AVROBIO
J. Kelly Ganjei, AmplifyBio
Scott R. Burger, MD, Advanced Cell and Gene Therapy
Matthew Cato
(2022)
Scientific presentation
Overview on Mission Bio’s Applications
Simone Formisano
Mission Bio EU Heme Symposium (2022)
REQUEST QUOTE